PDCD1 and non-small cell lung carcinoma: By targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), ICIs restore antitumor immune responses [6], leading to significant survival benefits in selected NSCLC patients [7].